Product Name | Lenalidomide |
Description |
Ubiquitin ligase inducer |
Purity | >98% (TLC); NMR (Conforms) |
CAS No. | 191732-72-6 |
Molecular Formula | C13H13N3O3 |
Molecular Weight | 259.26 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inducer |
Solubility | Soluble in DMSO (200 mM), Water (<1 mM) and Ethanol (<1 mM). |
Source | Synthetic |
Appearance | Powder |
SMILES | C1=CC=C(C3=C1C(N(C2C(NC(=O)CC2)=O)C3)=O)N |
InChI | InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) |
InChIKey | GOTYRUGSSMKFNF-UHFFFAOYSA-N |
Safety Phrases |
Classification: Acute toxicity, Oral (Category 4), Acute toxicity, Dermal (Category 4), Acute toxicity, Inhalation (Category 4), Reproductive toxicity (Category 1B) Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H301- Harmful if swallowed. H312- Harmful in contact with skin. H332- Harmful if inhaled. H360-May damage fertility or the unborn child. Precautionary statements: P261- Avoid breathing dust/fumes/gas/mist/vapors/spray. P263- Avoid contact during pregnancy/while nursing. P270- Do not eat, drink or smoke when using this product. P280- Wear protective gloves/protective clothing. P301+P310- IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. P302+P352- IF ON SKIN: Wash with plenty of soap and water. P304+P340- IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. P308+P313- IF exposed or concerned: Get medical advice/attention. P330- Rinse mouth. P405- Store locked up. P501- Dispose of contents/container to a licensed disposal company. |
Cite This Product | Lenalidomide (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-410) |
Alternative Names | 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione |
Research Areas | Cell Signaling, Post-translational Modifications |
PubChem ID | 216326 |
Scientific Background | Clinically, lenalidomide has proven to be effective in the treatment of multiple myeloma and other B cell diseases. It has the ability to selectively bind and ubiquitinate two lymphoid transcription factors, IKZF1 and IKZF2, via the CRBN-CRL4 ubiquitin ligase. This ultimately leads to the degradation of IKZF1 and IKZF2, which are both essential in myeloma cell survival. |
References |
1. Krönke J., et al. (2014) Science. 343(6168): 301-5. 2. Lu G., et al. (2014) Science. 343(6168): 305-9. |
Reviews
There are no reviews yet.